Journal of the European Academy of Dermatology and Venereology

Papers
(The H4-Index of Journal of the European Academy of Dermatology and Venereology is 44. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Announcement386
Editor's Picks January 2024251
Announcement146
132
Pioneers in Dermatology and Venereology: An Interview with Professor An Goossens128
Announcement124
2013–2023: A decade of progress and challenges in dermatology as reflected in JEADV119
Paradoxical joint and muscle pain in a patient treated with anifrolumab and belimumab112
Louis Adolphus Duhring: An enduring legacy110
Comparison of performance of SCORTEN, ABCD‐10 and Re‐SCORTEN in a cohort of patients with Stevens–Johnson syndrome/toxic epidermal necrolysis99
Course and outcome of chilblain‐like acral lesions during COVID‐19 pandemic89
High prevalence of extracutaneous involvement in ITG junctional epidermolysis bullosa84
Aquagenic pruritus: A web‐based survey study exploring itch characteristics, therapeutic options and patient perspectives80
Are non‐fungible tokens the barrier to realizing the Dermoverse?80
Impact of menopause on the skin…information still insufficient77
Comment on ‘Negative SARS‐CoV‐2 antibodies in patients with positive immunohistochemistry for spike protein in pityriasis rosea‐like eruptions’77
77
Issue Information76
71
Announcement70
Contact allergy may enhance further sensitization to new chemicals, but individual susceptibility traits are important for polysensitization68
Announcement68
The affliction of job, as painted by Jusepe de Ribera: A dermatological observation going back to the 17th century67
Comment on ‘Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity’ by Dupuis et al.66
Juvenile localized scleroderma: A single‐centre experience from India64
Dalbavancin for the treatment of severe hidradenitis suppurativa64
A case of eruptive halo nevi following COVID‐1964
The chicken or the egg of lymphopenia in atopic eczema63
The future of digital pills and their potential use in dermatological clinical trials62
Pharmacovigilance: The responsibility of all61
Automated dermatoscopic pattern discovery by clustering neural network output for human–computer interaction60
Educational, labour market and relationship outcomes in people with acne57
Rituximab in immunobullous disorders during the COVID‐19 pandemic: A systematic review of observational studies56
Multiple basal cell carcinomas revealing a biallelic MUTYH gene mutation in a 39‐year‐old male patient55
Editor’s Picks June 202555
Identification of children at risk for the development of severe paediatric plaque psoriasis: Findings from the prospective observational long‐term Child‐CAPTURE registry53
Peer review, scientific publishing and the law of reciprocity50
Long‐term patient‐reported perception and experience of methylprednisolone pulse with or without methotrexate in alopecia areata: A French retrospective single‐centre cohort46
Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: Multicentre study in daily practice46
Angiolymphoid hyperplasia with eosinophilia infiltrated by GATA3+ Th2 cells responding to dupilumab46
Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event 44
Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma44
Paediatric psoriasis and biologics: An evidence gap in plain sight44
Hidradenitis suppurativa: One step forward in timely diagnosis and appropriate treatment44
Acrodermatitis chronica atrophicans with clonal light chains and heavy chain rearrangement44
Commentary on vitiligo patient population and disease burden in France: VIOLIN Study results from the CONSTANCES cohort44
0.24222302436829